AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9987141
Drug: Adjuvanted influenza
RxNorm normalized name: Influenza, adjuvanted, quadrivalent, PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvanted influenza vaccine (FLUAD, Chiron Vaccines)
Trial: 9987141
Drug: Conventional non-adjuvanted
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional non-adjuvanted influenza vaccine
Trial: 7762525
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg beta-carotene/d for 6 d as synthetic all-trans-beta-carotene
Trial: 7762525
Drug: Natural beta-carotene
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural beta-carotene preparation (50:50 mixture of all-trans- and 6-cis-beta-carotene)
Trial: 7762525
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg all-trans-beta-carotene or either 66 or 100 mg of the natural 50:50 isomeric mixture (alternate-day supplementation for 23 d)
Trial: 17335365
Drug: Subgingival chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subgingival chlorhexidine varnish administration
Trial: 15252293
Drug: Sertraline (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (200 mg/day) for 14 weeks
Trial: 10201553
Drug: 7.0 g
RxNorm normalized name: OCTINOXATE 7.0 g in 100 g TOPICAL LIPSTICK [TREATMENT LIPSHINE SPF 15]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.0 g ispaghula/day
Trial: 10201553
Drug: 10.5 g
RxNorm normalized name: Gelatin Capsules, 10.5 gr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10.5 g ispaghula/day
Trial: 23331802
Drug: Probiotics administered
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics administered to 32 patients for 3 months post-pullthrough
Trial: 23331802
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered for 3 months post-pullthrough
Trial: 19748859
Drug: Echinacea/sage spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Echinacea/sage spray
Trial: 19748859
Drug: Chlorhexidine/lidocaine spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine/lidocaine spray
Trial: 18193695
Drug: Secnidazole tablet
DrugBank: Secnidazole (DB12834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Secnidazole tablet (reference)
Trial: 18193695
Drug: Secnidazole capsule
DrugBank: Secnidazole (DB12834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Secnidazole capsule (test)
Trial: 15867048
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (continuing omega-3 and omega-6 fatty acids)
Trial: 12186120
Drug: Liposomal amphotericin
RxNorm normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal amphotericin B (L-AMP-LRC-1)
Trial: 7867677
Drug: Desmin 370
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmin 370 (100 mg)
Trial: 7867677
Drug: Desmin 370
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmin 370 (200 mg)
Trial: 7867677
Drug: Desmin 370
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmin 370 (100 mg and 200 mg)
Trial: 773589
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of methyl‐CCNU and imidazole carboxamide (DTIC)
Trial: 15215815
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus Clopidogrel
Trial: 30783954
Drug: Control (Healthy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Healthy subjects receiving no-stent or antiplatelet therapy)
Trial: 21469195
Drug: Ropinirole prolonged
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropinirole prolonged release (PR) 2-24 mg/d
Trial: 21469195
Drug: Ropinirole immediate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropinirole immediate release (IR) 0.75-24 mg/d
Trial: 2153006
Drug: Ofloxacin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin (300 mg orally every 12 hours)
Trial: 2153006
Drug: Vancomycin/polymyxin (vancomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin/polymyxin (vancomycin 500 mg orally every 8 hours and polymyxin 100 mg orally every 8 hours)
Trial: 6383735
Drug: 0.1 percent
RxNorm normalized name: CAPSAICIN 0.1 g in 100 g TOPICAL CREAM [Capsaicin 0.1 Percent]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 percent amcinonide cream
Trial: 391500
Drug: 0.1 percent
RxNorm normalized name: CAPSAICIN 0.1 g in 100 g TOPICAL CREAM [Capsaicin 0.1 Percent]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 percent betamethasone valerate cream
Trial: 31439681
Drug: High-risk CC
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-risk CC genotype
Trial: 19114895
Drug: Alkaline phosphatase
RxNorm normalized name: Alkaline phosphatase
DrugBank: Alkaline Phosphatase (DB05768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alkaline phosphatase (AP) treatment
Trial: 15230337
Drug: Rabeprazole formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole formulation 1
Trial: 15230337
Drug: Rabeprazole formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole formulation 2
Trial: 12227646
Drug: DCLHb (10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DCLHb (10% solution, approximately 1000 mg/kg)
Trial: 7631339
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (air)
Trial: 378317
Drug: Mysteclin syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mysteclin syrup (tetracycline hydrochloride and amphotericin) used as a mouthwash
Trial: 21864626
Drug: 1mg intradermally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1mg intradermally (id) HIV‐DNA vaccine
Trial: 21864626
Drug: 3.8mg intramuscularly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.8mg intramuscularly (im) HIV‐DNA vaccine
Trial: 21864626
Drug: HIV‐DNA vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV‐DNA vaccine
Trial: 17763935
Drug: therapy to
RxNorm normalized name: COOL THERAPY Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: therapy to normalize homocysteine plasma level
Trial: 17763935
Drug: no therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no therapy to normalize homocysteine plasma level
Trial: 16445556
Drug: Buprenorphine (8-24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine (8-24 mg/day)
Trial: 16445556
Drug: Methadone (40-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone (40-100 mg/day)
Trial: 12563623
Drug: Sorbifer Durules
RxNorm normalized name: iron sorbitex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorbifer Durules (1 tablet/d) for 4 weeks
Trial: 8901659
Drug: Moderate oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate oral anticoagulation (INR 2.0 to 3.0)
Trial: 8901659
Drug: Standard oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oral anticoagulation (INR 3.0 to 4.5)
Trial: 6176321
Drug: Involved-field radiotherapy
RxNorm normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Involved-field radiotherapy plus six courses of MOPP chemotherapy
Trial: 6176321
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (MOPP-bleomycin)
Trial: 26314308
Drug: Low-osmolarity oral
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-osmolarity oral rehydration solution (ORS) (osmolarity: 245, sodium: 75) with added potassium (20 mmol/l)
Trial: 23364255
Drug: rosuvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosuvastatin (20 mg 2-4 hours before PCI)
Trial: 21371128
Drug: Tretinoin gel
RxNorm normalized name: Tretinoin Gel
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tretinoin gel microsphere 0.04% or 0.1%
Trial: 20469685
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (UDCA) at a dose of 10 mg/kg body weight once at night for 3 months
Trial: 15164114
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg iron supplementation (Fe group; n=978)
Trial: 15164114
Drug: Combined supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined supplementation of 10,000 IU vitamin A and 60 mg iron (VAFe group; n=1042)
Trial: 11529465
Drug: Up-front SCT
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up-front SCT with Dexa-BEAM chemotherapy followed by myeloablative regimens
Trial: 11529465
Drug: Salvage SCT
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salvage SCT with Dexa-BEAM chemotherapy followed by myeloablative regimens
Trial: 7515507
Drug: Prednisone (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (80 mg/day for 5 days)
Trial: 7515507
Drug: Acute dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Acute dexamethasone administration
Trial: 7515507
Drug: Chronic corticosterone
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic corticosterone administration
Trial: 3652932
Drug: Therapeutic drug
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic drug monitoring program for theophylline
Trial: 3652932
Drug: Reinstatement of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reinstatement of the therapeutic drug monitoring program
Trial: 31904295
Drug: Mindfulness-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based cognitive therapy (MBCT) + Treatment as Usual (TAU)
Trial: 31046423
Drug: Dabigatran (high-dose)
DrugBank: Dabigatran (DB14726)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran (high-dose)
Trial: 31046423
Drug: Dabigatran (low-dose)
RxNorm normalized name: ethinyl estradiol
DrugBank: Dabigatran (DB14726)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran (low-dose)
Trial: 26152434
Drug: Gabby (conversational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabby (conversational agent system)
Trial: 20534818
Drug: Edoxaban (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban (60 mg) administered with a standard high-fat meal
Trial: 20534818
Drug: Edoxaban (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban (60 mg) administered in a fasted state
Trial: 19671472
Drug: Cocoa powder
RxNorm normalized name: Cocoa powder
DrugBank: Cocoa (DB10977)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocoa powder (20 g/day) with 250 mL of skimmed milk
Trial: 19671472
Drug: Skimmed milk
RxNorm normalized name: Calcium fortified skimmed milk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skimmed milk (500 mL/day)
Trial: 17273659
Drug: Simvastatin, 20
RxNorm normalized name: Simvastatin, 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin, 20 mg/day (N = 20)
Trial: 17273659
Drug: Metformin, 1.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin, 1.7 g/day (N = 21)
Trial: 8555780
Drug: Automated blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated blood grouping by gel technology (ID-Sampler II)
Trial: 8555780
Drug: Routine microtitre
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine microtitre plate and gel techniques
Trial: 2925055
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg Is‐5‐Mn
Trial: 2925055
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg Is‐5‐Mn
Trial: 27643690
Drug: Licorice flavonoid
RxNorm normalized name: Licorice Flavanoid Oil
DrugBank: Glycyrrhiza glabra (DB14312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licorice flavonoid oil (LFO) 300 mg/day for 16 weeks
Trial: 27643690
Drug: Placebo (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (one capsule/day for 16 weeks)
Trial: 22893557
Drug: 3 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mL/kg calfactant by LMA (experimental)
Trial: 20687194
Drug: Narrative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrative therapy (NT) plus escitalopram
Trial: 15516378
Drug: Focused ultrasound
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Focused ultrasound therapy
Trial: 8005254
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg codeine
Trial: 18626140
Drug: Chlorpheniramine (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpheniramine (12 mg)
Trial: 18626140
Drug: Chlorpheniramine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpheniramine plus ephedrine (Chlorphedra: 12 mg C + 50 mg ephedrine)
Trial: 9261702
Drug: Targeted antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted antibiotics (for TBSA ≥ 35%)
Trial: 3536400
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g sucralfate suspension four times daily
Trial: 1484022
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg ranitidine tablet twice daily
Trial: 18338263
Drug: Neostigmine 2
RxNorm normalized name: neostigmine 2.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine 2 mg and glycopyrrolate 0.4 mg intramuscularly
Trial: 1403999
Drug: Couple therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Couple therapy (five sessions)
Trial: 1403999
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no couple therapy)
Trial: 2988737
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy twice a week (40.00 Gy/5 weeks) with misonidazole 1.2 g/m2 given orally 3 1/2 to 4 hours before treatment
Trial: 2988737
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy twice a week (40.00 Gy/5 weeks) with placebo
Trial: 2988737
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy five times a week (50.00 Gy/5 weeks) with misonidazole 0.48 g/m2 given orally 3 1/2 to 4 hours before treatment
Trial: 2988737
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy five times a week (50.00 Gy/5 weeks) with placebo
Trial: 2988737
Drug: CCNU chemotherapy
RxNorm normalized name: Lomustine
DrugBank: Lomustine (DB01206)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CCNU chemotherapy (120 mg/m2 every 6 weeks)
Trial: 27600013
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia and patient-controlled intravenous analgesia (PCIA)
Trial: 19255992
Drug: Sublingual midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sublingual midazolam (0.3 mg/kg)
Trial: 9877257
Drug: Parents as
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parents as the agents of change (experimental intervention)
Trial: 9877257
Drug: Children as
RxNorm normalized name: AZELASTINE HYDROCHLORIDE 205.5 ug NASAL SPRAY, METERED [Children Astepro Allergy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children as the agents of change (conventional intervention)
Trial: 8078438
Drug: Cyclic parenteral
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic parenteral nutrition
Trial: 8078438
Drug: Continuous nutrient
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous nutrient infusion
Trial: 30629770
Drug: G + T
RxNorm normalized name: Gemcitabine + Trastuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G + T
Trial: 24392462
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (72 patients)
Trial: 19887581
Drug: Higher serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher serum total cholesterol concentration (high versus low quintile, >276.7 versus <203.9 mg/dL)
Trial: 19887581
Drug: Greater HDL
RxNorm normalized name: greater celandine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Greater HDL cholesterol (high versus low quintile, >55.3 versus <36.2 mg/dL)
Trial: 14987626
Drug: Subcutaneous needle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous needle insertion
Trial: 11669568
Drug: Nursing and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nursing and treatment routines
Trial: 9853541
Drug: Wheat bran
RxNorm normalized name: Wheat bran
DrugBank: Wheat bran (DB10685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wheat bran supplement (high-fiber control)
Trial: 1095283
Drug: Fenmetozole (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenmetozole (100 mg and 200 mg)
Trial: 30604197
Drug: Mannuronic acid
RxNorm normalized name: mannuronate methylsilanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mannuronic acid (500 mg, two capsules per day orally for 12 weeks)
Trial: 29231473
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy group (acupuncture + modified weitong xiaopi formula)
Trial: 29231473
Drug: Chinese herbal
RxNorm normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbal medicine group (modified weitong xiaopi formula)
Trial: 29231473
Drug: Western medication
RxNorm normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medication group (mosapride citrate capsules)
Trial: 23739503
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg of L-carnitine per day
Trial: 23739503
Drug: 2000 mg
RxNorm normalized name: bran 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 mg of L-carnitine per day
Trial: 23739503
Drug: Basic therapy
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic therapy only (control group)
Trial: 17416110
Drug: Ketamine (n=20):
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (n=20): bolus dose of 0.5 mg x kg(‐1) followed by continuous infusion of 2 microg x kg(‐1) x min(‐1) before surgery.
Trial: 9301431
Drug: Intravenous L-arginine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous L-arginine 8 g
Trial: 9301431
Drug: Intravenous L-arginine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous L-arginine 30 g
Trial: 7019033
Drug: lysozyme chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lysozyme chloride at doses of 60 to 170 mg/day for 4 to 24 weeks
Trial: 20455246
Drug: Pexacerfont 100
RxNorm normalized name: Pexacerfont
DrugBank: Pexacerfont (DB12572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pexacerfont 100 mg/day
Trial: 11918753
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (enalapril 10 mg/day and eprosartan 300 mg/day)
Trial: 8973851
Drug: epirubicin 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epirubicin 75 mg/m2
Trial: 8973851
Drug: mitozantrone 14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mitozantrone 14 mg/m2
Trial: 1333098
Drug: Conjugated estrogens
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated estrogens at 0.625 mg per day
Trial: 1333098
Drug: Conjugated estrogens
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated estrogens at 1.25 mg per day
Trial: 20214894
Drug: Metformin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin therapy for 3 months
Trial: 27690762
Drug: AS03-adjuvanted trivalent
RxNorm normalized name: AS03 Adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS03-adjuvanted trivalent inactivated influenza vaccine (AS03-TIV)
Trial: 27690762
Drug: Non-adjuvanted trivalent
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-adjuvanted trivalent inactivated influenza vaccine (TIV)
Trial: 27690762
Drug: Statistical model
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statistical model based on A/H3N2 attack rates and HI antibody titers